These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 28189463)

  • 1. Evaluating the performance of the Montreal Cognitive Assessment in early stage Parkinson's disease.
    Kletzel SL; Hernandez JM; Miskiel EF; Mallinson T; Pape TL
    Parkinsonism Relat Disord; 2017 Apr; 37():58-64. PubMed ID: 28189463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor structure of the Montreal Cognitive Assessment items in a sample with early Parkinson's disease.
    Benge JF; Balsis S; Madeka T; Uhlman C; Lantrip C; Soileau MJ
    Parkinsonism Relat Disord; 2017 Aug; 41():104-108. PubMed ID: 28572020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease.
    Brennan L; Siderowf A; Rubright JD; Rick J; Dahodwala N; Duda JE; Hurtig H; Stern M; Xie SX; Rennert L; Karlawish J; Shea JA; Trojanowski JQ; Weintraub D
    Parkinsonism Relat Disord; 2016 Apr; 25():21-6. PubMed ID: 26923524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson's disease.
    Uysal-Cantürk P; Hanağası HA; Bilgiç B; Gürvit H; Emre M
    Eur J Neurol; 2018 Jan; 25(1):148-153. PubMed ID: 28941002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition.
    Phannarus H; Muangpaisan W; Siritipakorn P; Chotinaiwattarakul W
    Psychogeriatrics; 2020 Jan; 20(1):20-27. PubMed ID: 30912230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire.
    Brennan L; Siderowf A; Rubright JD; Rick J; Dahodwala N; Duda JE; Hurtig H; Stern M; Xie SX; Rennert L; Karlawish J; Shea JA; Trojanowski JQ; Weintraub D
    Mov Disord; 2016 Jan; 31(1):126-34. PubMed ID: 26249849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive screening in Parkinson's disease: Comparison of the Parkinson Neuropsychometric Dementia Assessment (PANDA) with 3 other short scales.
    Gasser AI; Calabrese P; Kalbe E; Kessler J; Rossier P
    Rev Neurol (Paris); 2016 Feb; 172(2):138-45. PubMed ID: 26494570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease.
    Holden SK; Medina LD; Hoyt B; Sillau SH; Berman BD; Goldman JG; Weintraub D; Kluger BM
    Mov Disord; 2018 Nov; 33(11):1760-1768. PubMed ID: 30306618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.
    Zadikoff C; Fox SH; Tang-Wai DF; Thomsen T; de Bie RM; Wadia P; Miyasaki J; Duff-Canning S; Lang AE; Marras C
    Mov Disord; 2008 Jan; 23(2):297-9. PubMed ID: 18044697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance.
    Burdick DJ; Cholerton B; Watson GS; Siderowf A; Trojanowski JQ; Weintraub D; Ritz B; Rhodes SL; Rausch R; Factor SA; Wood-Siverio C; Quinn JF; Chung KA; Srivatsal S; Edwards KL; Montine TJ; Zabetian CP; Leverenz JB
    Mov Disord; 2014 Sep; 29(10):1258-64. PubMed ID: 25073717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the Turkish Version of the Montreal Cognitive Assessment Scale (MoCA-TR) in patients with Parkinson's disease.
    Ozdilek B; Kenangil G
    Clin Neuropsychol; 2014; 28(2):333-43. PubMed ID: 24528299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson's disease.
    Hendershott TR; Zhu D; Llanes S; Poston KL
    Parkinsonism Relat Disord; 2017 May; 38():31-34. PubMed ID: 28215728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease-cognitive rating scale: psychometrics for mild cognitive impairment.
    Fernández de Bobadilla R; Pagonabarraga J; Martínez-Horta S; Pascual-Sedano B; Campolongo A; Kulisevsky J
    Mov Disord; 2013 Sep; 28(10):1376-83. PubMed ID: 23873810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease.
    Gill DJ; Freshman A; Blender JA; Ravina B
    Mov Disord; 2008 May; 23(7):1043-1046. PubMed ID: 18381646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease.
    van Steenoven I; Aarsland D; Hurtig H; Chen-Plotkin A; Duda JE; Rick J; Chahine LM; Dahodwala N; Trojanowski JQ; Roalf DR; Moberg PJ; Weintraub D
    Mov Disord; 2014 Dec; 29(14):1809-15. PubMed ID: 25381961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.
    Hendershott TR; Zhu D; Llanes S; Zabetian CP; Quinn J; Edwards KL; Leverenz JB; Montine T; Cholerton B; Poston KL
    Mov Disord; 2019 Feb; 34(2):285-291. PubMed ID: 30776152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychological profile of patients with Parkinson's disease without dementia.
    Janvin C; Aarsland D; Larsen JP; Hugdahl K
    Dement Geriatr Cogn Disord; 2003; 15(3):126-31. PubMed ID: 12584427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of psychometric properties of the Beijing version of Montreal Cognitive Assessment in patients with idiopathic Parkinson's disease in China.
    Nie K; Zhang Y; Wang L; Zhao J; Huang Z; Gan R; Li S; Wang L
    J Clin Neurosci; 2012 Nov; 19(11):1497-500. PubMed ID: 22959678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.
    Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R
    J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.